• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 12.09
  • VXN 15.15
  • VXO 12.04
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

RNN (Rexahn Pharmaceuticals Inc.)
Last Trade 6.24 Dividend/Share 0 PE Ratio -11.14
Date April 18-2019 Dividend Yield 0.000 Return on Assets -64.82
Change -0.06 ExDividend Date 0 Return on Capital null
Bid null Latest EPS -5.4 Price/Sale null
Ask null LatestEPS Date 2018-12-31 Price to Book 2.38
Volume null EPS ttm -0.560 Institutional % 13.1
Avg Volume 0.31M Shares Outstanding 4.02M Insider % null
Open 6.19 Float 0M Short Ratio 0.760
Prev Close 6.3 Return On Equity -105.14 5 Year Change % -0.948
High 6.37 Consensus EPS -0.08 2 Year Change % -0.876
Low 6.12 No. of Estimate 3.000 1 Year Change % -0.671
52 Week High 28.56 EPS Surprise $ null YTD Change % -0.458
52 Week Low 4.7501 EPS Surprise Percent 0 6 Month Change % -0.527
52 Week Change -67.500 EBITDA 0M 3 Month Change % -0.485
50 Day MA 6.60802 Revenue 0M 1 Month Change % -0.047
200 Day MA Gross Profit 0M 5 Day Change % 0.112
Market Cap 25.12M Cash 0M 30 Day Change % -0.085
Beta 0.706519 Debt 0M Stock Exchange NYSE American
Sector Healthcare Revenue Per Share 0 Short Interest 22242
Short Date 2019-03-29 Revenue Per Employee 0 Short Ratio 0.760
Data courtesy of IEX
Company Profile

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction, and other unmet medical needs in the United States. Its drug candidates in Phase II clinical trials include Archexin, the lead anticancer drug candidate is an inhibitor of the protein kinase Akt for the treatment of pancreatic cancer and renal cell carcinoma; Serdaxin for the treatment of depression and neurodegenerative disorders; and Zoraxel, a drug for sexual dysfunction that modulates the sexual activity control center in the brain. Its pre-clinical pipeline products include RX-1792, a molecule targeted anticancer drug candidate; RX-5902, a molecule microtubule inhibitor anticancer drug candidate; RX-3117, a molecule anti-metabolite nucleoside anticancer drug candidate; RX-8243, a molecule aurora kinase inhibitor anticancer drug candidate; RX-0201-Nano, nanoliposomal anticancer Akt-1 inhibitor; RX-0047-Nano, nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101 & RX-21202, a nano-polymer anticancer. The company has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries; TheraTarget, Inc.; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; and Revaax Pharmaceuticals LLC. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.